Home | Business News | Browse by Publication | M | M2 Presswire

Acuity Pharmaceuticals, Froptix Corporation and eXegenics Inc. Announce an Agreement to Merger.

Article Excerpt
M2 PRESSWIRE-27 March 2007-Afternoon Movers: Acuity Pharmaceuticals, Froptix Corporation and eXegenics Inc. Announce an Agreement to Merger(C)1994-2007 M2 COMMUNICATIONS LTD

RDATE:27032007

Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Today's activity on the market has brought this company to the attention of our research team. eXegenics, Inc. (OTC BB: EXEG), is responding to the attention of investors. Our goal is to create a community of international investors who consistently and effectively capitalize on the enormous gains the small-cap Canadian and American exchanges offer.

Acuity Pharmaceuticals and Froptix Corporation, privately owned pharmaceutical companies developing novel drugs to treat serious diseases of the eye, and eXegenics, Inc. (OTC Bulletin Board: EXEG), a publicly-traded company with no active operations, have executed a merger agreement that will bring the three companies under one corporate umbrella. The combined company will be re-named Opko Corporation. It will be headquartered in Miami, Florida and intends to apply to have its shares listed on the American Stock Exchange (AMEX).

Acuity's product portfolio includes the pioneering gene silencing agent bevasiranib, which has successfully completed Phase II clinical trials for wet...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!